The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia

被引：1

作者：

Jovanovic-Cupic, Snezana ^{[1
]}

Glisic, Sanja ^{[2
]}

Stanojevic, Maja ^{[3
]}

Nozic, Darko ^{[4
]}

Petrovic, Nina ^{[1
]}

Mandusic, Vesna ^{[1
]}

Krajnovic, Milena ^{[1
]}

机构：

[1] Univ Belgrade, Inst Nucl Sci, Lab Radiobiol & Mol Genet, POB 522, Belgrade 11000, Serbia

[2] Univ Belgrade, Inst Nucl Sci, Ctr Multidisciplinary Res, POB 522, Belgrade 11000, Serbia

[3] Univ Belgrade, Fac Med, Inst Microbiol & Immunol, Belgrade 11000, Serbia

[4] Mil Med Acad, Clin Infect & Trop Dis, Belgrade 11000, Serbia

来源：

ARCHIVES OF VIROLOGY | 2016年 / 161卷 / 05期

关键词：

SUSTAINED VIROLOGICAL RESPONSE; ALPHA PLUS RIBAVIRIN; FIBROSIS PROGRESSION; COMBINATION THERAPY; ION-CHANNEL; VIRUS P7; HCV P7; PEGINTERFERON; PROTEIN; RNA;

D O I：

10.1007/s00705-016-2777-z

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p < 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p < 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p < 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.

引用

页码：1189 / 1198

页数：10

共 50 条

[21] Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C [J].

S. K. Tohra ;

S. Taneja ;

S. Ghosh ;

B. K. Sharma ;

A. Duseja ;

R. K. Dhiman ;

A. Das ;

Y. K. Chawla .

Digestive Diseases and Sciences, 2011, 56

[22] Efficacy and Safety of Telaprevir, Pegylated Interferon α-2b and Ribavirin Triple Therapy in Japanese Patients Infected with Hepatitis C Virus Genotype 1b [J].

Kawaguchi, Yasunori ;

Iwane, Shinji ;

Kumagai, Takanori ;

Yanagita, Kimihiko ;

Yasutake, Tsutomu ;

Ide, Yasushi ;

Otsuka, Taiga ;

Eguchi, Yuichiro ;

Ozaki, Iwata ;

Akiyama, Takumi ;

Kawazoe, Seiji ;

Mizuta, Toshihiko .

INTERNAL MEDICINE, 2015, 54 (20) :2551-2560

[23] Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C [J].

Chayama, Kazuaki ;

Hayes, C. Nelson ;

Yoshioka, Kentaro ;

Moriwaki, Hisataka ;

Okanoue, Takeshi ;

Sakisaka, Shotaro ;

Takehara, Tetsuo ;

Oketani, Makoto ;

Toyota, Joji ;

Izumi, Namiki ;

Hiasa, Yoichi ;

Matsumoto, Akihiro ;

Nomura, Hideyuki ;

Seike, Masataka ;

Ueno, Yoshiyuki ;

Yotsuyanagi, Hiroshi ;

Kumada, Hiromitsu .

HEPATOLOGY RESEARCH, 2010, 40 (12) :1155-1167

[24] Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C Patients with Genotype 1b and Low-virus Load [J].

Arase, Yasuji ;

Suzuki, Fumitaka ;

Akuta, Norio ;

Sezaki, Hitomi ;

Suzuki, Yoshiyuki ;

Kawamura, Yusuke ;

Kobayashi, Masahiro ;

Hosaka, Tetsuya ;

Yatsuji, Hiromi ;

Hirakawa, Miharu ;

Saito, Satoshi ;

Ikeda, Kenji ;

Kobayashi, Mariko ;

Kumada, Hiromitsu .

INTERNAL MEDICINE, 2009, 48 (05) :253-258

[25] Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C [J].

Yano, Yoshihiko ;

Seo, Yasushi ;

Miki, Akira ;

Saito, Masaya ;

Kato, Hirotaka ;

Hamano, Ken-Ichi ;

Oya, Manabu ;

Ouchi, Sachiko ;

Fujisawa, Takashi ;

Yamada, Hajime ;

Yamashita, Yukimasa ;

Tani, Satoshi ;

Hirohata, Shigeya ;

Yoon, Seitetsu ;

Kitajima, Naoto ;

Kitagaki, Kazunari ;

Kawara, Akira ;

Nakashima, Takatoshi ;

Yu, Hosai ;

Maeda, Tetsuo ;

Azuma, Takeshi ;

El-Shamy, Ahmed ;

Hotta, Hak ;

Hayashi, Yoshitake .

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 30 (05) :1048-1052

[26] Shorter duration of pegylated interferon plus ribavirin therapy for chronic hepatitis c genotype 1 patients who achieve early virological response [J].

Omesh, Goyal ;

Sood, Ajit ;

Midha, Vandana .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 :18-19

[27] Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy [J].

Hayashi, K. ;

Katano, Y. ;

Ishigami, M. ;

Itoh, A. ;

Hirooka, Y. ;

Nakano, I. ;

Urano, F. ;

Yoshioka, K. ;

Toyoda, H. ;

Kumada, T. ;

Goto, H. .

JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) :280-286

[28] Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis [J].

Thong, Vo Duy ;

Poovorawan, Kittiyod ;

Tangkijvanich, Pisit ;

Wasitthankasem, Rujipat ;

Vongpunsawad, Sompong ;

Poovorawan, Yong .

INTERVIROLOGY, 2015, 58 (06) :373-381

[29] Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy [J].

Sood, Ajit ;

Midha, Vandana ;

Goyal, Omesh .

ANNALS OF HEPATOLOGY, 2014, 13 (05) :503-509

[30] An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads [J].

Sezaki, Hitomi ;

Suzuki, Fumitaka ;

Akuta, Norio ;

Yatsuji, Hiromi ;

Hosaka, Tetsuya ;

Kobayashi, Masahiro ;

Suzuki, Yoshiyuki ;

Arase, Yasuji ;

Ikeda, Kenji ;

Miyakawa, Yuzo ;

Kumada, Hiromitsu .

INTERVIROLOGY, 2009, 52 (01) :43-48

← 1 2 3 4 5 →